Gelteq (GELS) Competitors $2.30 -0.04 (-1.71%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. OTLK, ASRT, MGX, OKYO, ABOS, TELO, ANL, VHAQ, MCRB, and RPTXShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Outlook Therapeutics (OTLK), Assertio (ASRT), Metagenomi (MGX), OKYO Pharma (OKYO), Acumen Pharmaceuticals (ABOS), Telomir Pharmaceuticals (TELO), Adlai Nortye (ANL), Viveon Health Acquisition (VHAQ), Seres Therapeutics (MCRB), and Repare Therapeutics (RPTX). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Outlook Therapeutics Assertio Metagenomi OKYO Pharma Acumen Pharmaceuticals Telomir Pharmaceuticals Adlai Nortye Viveon Health Acquisition Seres Therapeutics Repare Therapeutics Outlook Therapeutics (NASDAQ:OTLK) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership. Do insiders & institutionals have more ownership in OTLK or GELS? 11.2% of Outlook Therapeutics shares are held by institutional investors. 4.8% of Outlook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, OTLK or GELS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$75.37M-$0.91-2.02GelteqN/AN/AN/AN/AN/A Is OTLK or GELS more profitable? Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -225.12% Gelteq N/A N/A N/A Do analysts prefer OTLK or GELS? Outlook Therapeutics currently has a consensus price target of $9.60, indicating a potential upside of 421.74%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Outlook Therapeutics is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor OTLK or GELS? Outlook Therapeutics received 167 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16770.76% Underperform Votes6929.24% GelteqN/AN/A Does the media refer more to OTLK or GELS? In the previous week, Outlook Therapeutics had 3 more articles in the media than Gelteq. MarketBeat recorded 9 mentions for Outlook Therapeutics and 6 mentions for Gelteq. Gelteq's average media sentiment score of 0.81 beat Outlook Therapeutics' score of 0.39 indicating that Gelteq is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Outlook Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOutlook Therapeutics beats Gelteq on 7 of the 9 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.71M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E RatioN/A8.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / BookN/A6.597.064.69Net IncomeN/A$143.75M$3.23B$248.14M7 Day Performance34.50%3.72%2.67%2.39%1 Month Performance59.72%11.01%8.82%6.05%1 Year PerformanceN/A3.87%31.44%13.60% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$2.30-1.7%N/AN/A$21.71MN/A0.00N/ANews CoverageGap DownOTLKOutlook Therapeutics1.434 of 5 stars$1.91+3.2%$10.20+434.0%-76.5%$64.12MN/A-0.2620News CoverageASRTAssertio2.4485 of 5 stars$0.67-0.5%$2.75+312.5%-39.6%$63.85M$119.00M-0.9120Positive NewsMGXMetagenomi2.3103 of 5 stars$1.70-4.0%$13.00+664.7%-76.8%$63.55M$45.26M-0.81236OKYOOKYO Pharma2.1797 of 5 stars$1.88+0.5%$7.00+272.3%+64.9%$63.27MN/A0.007News CoverageGap UpABOSAcumen Pharmaceuticals2.1868 of 5 stars$1.07+2.9%$7.33+585.4%-57.0%$63.00MN/A-0.7820Positive NewsShort Interest ↑Analyst RevisionTELOTelomir Pharmaceuticals2.0293 of 5 stars$2.11+3.4%$15.00+610.9%-64.2%$62.80MN/A-3.641ANLAdlai Nortye1.32 of 5 stars$1.70+3.7%$9.00+429.4%-50.2%$62.73M$5M0.00127VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeMCRBSeres Therapeutics3.5637 of 5 stars$7.13+1.9%$73.67+933.2%-49.5%$62.26M$126.33M-31.00330Positive NewsRPTXRepare Therapeutics2.452 of 5 stars$1.45flat$4.50+210.3%-62.1%$62.19M$1.07M-0.73180 Related Companies and Tools Related Companies Outlook Therapeutics Competitors Assertio Competitors Metagenomi Competitors OKYO Pharma Competitors Acumen Pharmaceuticals Competitors Telomir Pharmaceuticals Competitors Adlai Nortye Competitors Viveon Health Acquisition Competitors Seres Therapeutics Competitors Repare Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GELS Stock Free GELS Stock Alerts